Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29829398 | 1.00 | HTT (0.66) | HTTTDP1ALDH1A1HIF1APKM | |
| SCHEMBL2938530 | 0.88 | HTT (0.53) | HTTTDP1ALDH1A1HIF1APKM | |
| SCHEMBL11689380 | 0.86 | PDGFRB (0.51) | HTTTDP1ALDH1A1HIF1APKM | |
| SCHEMBL296681 | 0.85 | TDP1 (0.64) | HTTTDP1ALDH1A1HIF1APKM | |
| SCHEMBL25356037 | 0.84 | HSPB1 (0.58) | HTTTDP1ALDH1A1HIF1AHSPB1 | |
| SCHEMBL29441283 | 0.82 | HTT (0.72) | HTTTDP1ALDH1A1PKMLMNA | |
| SCHEMBL527567 | 0.82 | HTT (0.72) | HTTTDP1ALDH1A1PKMLMNA | |
| SCHEMBL20335461 | 0.82 | HTT (0.49) | HTTTDP1ALDH1A1HIF1APKM | |
| SCHEMBL5839346 | 0.81 | ALDH1A1 (0.56) | HTTTDP1ALDH1A1HIF1ALMNA | |
| SCHEMBL31506375 | 0.81 | CYP19A1 (0.57) | HTTTDP1ALDH1A1HIF1APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306708-A | FLT3-HDAC double-target inhibitor and preparation method and application thereof | 山东大学 | 2025-01-14 | — | — | CN | claimed |
| CN-117913367-A | Preparation method of composite organic solvent, electrolyte and lithium-sulfur battery | 东方电气集团科学技术研究院有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-116768729-A | Synthesis method of 2-fluoro-5-nitroanisole | 西安宇特邦医药科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4727943-A1 | INHIBITORS OF MET KINASE | Celyn Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| CN-1158238-C | Haloacetophenone derivative and its synthesis process | 大连绿源新化学药业股份有限公司 | 2004-07-21 | — | — | CN | disclosed |
| CN-1447797-A | New process for preparing quinolone-carboxylic acid | DALIAN LYNCHEM CO LTD (CN) | 2003-10-08 | — | — | CN | disclosed |
| CN-1320591-A | Haloacetophenone derivative and its synthesis process | LUYUAN INDUSTRY CO LTD DALIAN (CN) | 2001-11-07 | — | — | CN | disclosed |
| US-5948906-A | CROWN ETHERS THAT CONTAIN AT LEAST ONE CORE NITROGEN THAT ARE LINKED VIA THE CORE NITROGEN(S) TO AT LEAST ONE FLUOROPHORE THAT CONTAINS AN ADDITIONAL HETEROAROMATIC LIGANDING THE CENTER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0369733-B1 | Fluorescent indicator dyes for alkali metal cations, their preparation and use | UNIV CALIFORNIA (US) | 1996-02-21 | — | — | EP | disclosed |
| US-5134232-A | Diagnosis; concentration in blood | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-07-28 | — | — | US | disclosed |
| US-4044049-A | Phenyl benzoic acid compounds | MERCK & CO., INC. (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | HTT 3312/4885TDP1 1531/4885ALDH1A1 999/4885 |
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | CASP6, CASP3, BAX | HTT 1662/4885TDP1 554/4885ALDH1A1 4013/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | HTT 536/4885TDP1 2036/4885ALDH1A1 1919/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | HTT 3478/4885TDP1 3835/4885ALDH1A1 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.